{"id":"W4283379313","doi":"10.1097/01.hs9.0000850132.55221.5c","title":"PB1820: CD47-BLOCKER TTI-622 COMBINED WITH AZACITIDINE IN PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA (AML) AND WITH AZACITIDINE + VENETOCLAX IN ELDERLY OR UNFIT PATIENTS WITH TP53-WILDTYPE AML","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Phagocytosis and Immune Regulation","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Trillium Therapeutics (Canada)","funders":"","keywords":"Venetoclax; Azacitidine; CD47; Medicine; Myeloid leukemia; Myeloid; Hypomethylating agent; Leukemia; Cancer research; Oncology; Minimal residual disease; Internal medicine; Immunology; Chronic lymphocytic leukemia; Biology; Receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002440435,0.0003095628,0.0008420617,0.0002070744,0.0001963419,0.0002745316,0.0002092128,0.0002930245,0.0009140988],"category_scores_gemma":[0.0004387391,0.0001742282,0.0003187301,0.0002455342,0.0001972997,0.000226109,0.000129695,0.0007143299,0.0002262675],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003076046,"about_ca_system_score_gemma":0.0002712844,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004834611,"about_ca_topic_score_gemma":0.0009200751,"domain_scores_codex":[0.9998685,0.00003986733,0.00001141271,0.00003103035,0.00002211506,0.00002699795],"domain_scores_gemma":[0.9998097,0.00003479301,0.00004177934,0.00001177627,0.00001143346,0.00009047751],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2636333,0.008979065,0.2275944,0.001142949,0.00171808,0.008048697,0.000997348,0.004294352,0.2458533,0.0003852803,0.002898746,0.2344545],"study_design_scores_gemma":[0.01837507,0.2894248,0.6098974,0.0001277748,0.002317667,0.01424559,0.0003652663,0.005717253,0.04364542,0.0002546312,0.01554097,0.00008821124],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9959406,0.003111011,0.0001144128,0.000085265,0.00001993865,0.00004202046,0.00008370892,0.00001559176,0.0005874325],"genre_scores_gemma":[0.9985067,0.0007497442,0.0001291404,0.00006448706,0.00003644283,0.00002295825,0.0001637111,0.00000340218,0.0003233662],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0009140988,"threshold_uncertainty_score":0.003057957,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.005121433250560848,"score_gpt":0.1900629290884207,"score_spread":0.1849414958378598,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}